International Journal of Medical Science and Pharmaceutical Research

Levers used for pharmaceutical promotion, medical samples, and various gifts play a key role in the strategy. The aim of this study is to evaluate the impact these different free gifts can have on the activity of doctors and pharmacists in Yaoundé.

This was a mixed-methods descriptive and analytical study conducted from August 2023 to January 2024 in the city of Yaoundé. A questionnaire was used to collect data from 464 physicians, and an interview guide was administered to 11 pharmacists. The data were analyzed using SPSS 21, Excel, Epi Info version 7.0, and Word software.

71.5% of respondents acknowledged receiving a medical sample, 45.6% changed their prescribing habits after receiving one, and 55.6% of their colleagues saw their prescribing habits change after receiving a medical sample. 77.6% of respondents had received a meal offered by pharmaceutical representatives, but only 28% changed their prescribing habits after receiving it; 19.6% of respondents acknowledged receiving a valuable gift, and 53.8% of these changed their prescribing habits after receiving it. Those who receive medical samples are 3.5 times more likely to change their prescribing habits than those who do not (p-value = 0.002). The risk is lower with receiving a gift, as well as with receiving a meal.

This study reveals that free gifts offered to healthcare professionals influence their prescribing habits. Free medical samples have a greater impact than meals and valuable gifts. However, in some cases, these gifts trigger a psychological reactance in these prospective patients, leading to effects contrary to those intended.

free donations, pharmaceutical promotion, medical sample, gifts, Yaoundé.

1. Lam MD, (2004). A $20 billion bill and plenty of change. Pharmaceutical Executive Sept 1.
2. Wilhelm, MC; Gavard-Perret, ML. and Gemayel Y. (2019). The effects of the characteristics of promotional gifts offered by pharmaceutical companies on physicians' prescriptions: The mediating role of situational reactance, Décisions Marketing 2019/4 (No. 96), pp. 125-140, EMS Editions, ISSN 0779-738, DOI 10.7193/DM.096.125.140
3. https://nurses.3cdn.net/e74ab9a3e937fe5646_ afm6bh0u9.pdf – The R&D Smokescreen – October 20th, 2016, Prepared by the Institute for Health and Socio-Economic Policy, site consulted in November 2024
4. https://www.regardscitoyens.org/sunshineces-245-millions-deuros-que-les-laboratoirespharmaceutiques-veulent-cacher/, site consulted in November 2024.
5. Brody H. (2005). The company we keep: why physicians should refuse to see pharmaceutical representatives. Annals of Family Medicine 3: 82-86.
6. Sierles FS et al. (2005). Medical students' exposure to and attitudes about drug company interactions: a national survey. Journal of the American Medical Association, 294(9 ): 1034-42.
7. Biegler P. and Vargas P. (2013). Ban the sunset? Nonpropositional content and regulation of pharmaceutical advertising, American Journal of Bioethics, 13(5): 3-13.
8. Angell M (2004). The truth about the drug companies: how they deceive us and what to do about it. New York, Random House.
9. Health Action International. Fact or Fiction, 2016: What Healthcare Professionals Need to Know about Pharmaceutical Marketing in the European Union – Health Action International. 2016. https://haiweb.org/publication/fact-or-fiction-pharmaceutical-marketing-in-the-european-union
10. World Health Organization, Health Action International, (2009). Understanding and responding to pharmaceutical promotion: a practical guide. 2009. http://haiweb.org/wp-content/uploads/2015/05/Pharma-Promotion-Guide
11. Bombardier C, Laine L, Reicin A et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New England Journal of Medicine, 2000, 343(21 ): 1520-8.
12. Graham DJ, Campen D, Hui R et al. (2005). Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non- selective non-steroidal antiinflammatory drugs: nested case-control study. Lancet 2005, 365: 475-481.
13. French Law No. 2011-2012 of December 29, 2011 relating to the strengthening of the health safety of medicines and health products. 2011-2012 Dec 29, 2011.
14. Fabbri A. Santos Ancel la, Mezinska S, Mulinari S, Mintzes B. (2018). Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries. Int J Health Policy Manag e 2018;7: 504-9. doi: 10.15171/ijhpm.2018.20
15. Market profile. (2014). The health market in Lebanon , Business France, September 2014.
16. Tiam W, Dohbit JS, Ngo Likeng JL, Ahmadou S, Martin Baane M. (2024). Medical visit activity in Mfoundi division: extend and effect on medical and pharmaceutical practice. Texila International Journal of Public Health ISSN: 2520-3134, DOI: 10.21522/TIJPH.2013.12. 03.Art 015
17. Marco CA, Moskop JC, Solomon RC, Geiderman JM, Larkin GL (2006). Gifts to physicians from the pharmaceutical industry: An ethical analysis. Annals of Emergency Medicine 2006; 48: 513-21.
18. Chew LD, O'Young TS, Hazlet TK, Bradley KA, Maynard C, Lessler DS (2000). A physician survey of the effect of drug sample availability on physicians' behavior. Journal of General Internal Medicine 2000; 15: 478-83.
19. Adair RF, Holmgren LR. (2005). Do drug samples influence resident prescribing behavior? A randomized trial. American Journal of Medicine 2005; 118: 881-4.
20. Brezis M. (2008). Big pharma and health care: Unsolvable conflict of interests between private enterprise and public health. Israel Journal of Psychiatry and Related Sciences 2008; 45: 83-9.
21. Katz D, Caplan AL, Merz JF. (2003). All gifts large and small - Toward an understanding of the ethics of pharmaceutical industry gift-giving. American Journal of Bioethics 2003; 3: 39-46.
22. Brett AS, Burr W, Moloo MA. (2003). Are gifts from pharmaceutical companies ethically problematic? A survey of physicians. Archives of Internal Medicine 2003; 163: 2213-8.
23. Dorsch MJ and Kelley W. (1994), An investigation into the intentions of purchasing executives to reciprocate vendor gifts, Journal of Marketing Science, 22(4): 315-327.
24. Moskop JC, Iserson KV, Aswegan AL, Larkin GL and Schears RM (2012). Gifts to physicians from industry: the debate evolves, Annals of Emergency Medicine , 59(2): 89-97.
25. Wendlandt M. and Schrader U. (2007). Consumer reactance against loyalty programs, Journal of Consumer Marketing , 24(5): 293-304.
26. Brehm, S. and Brehm, J. (1981). Psychological reactance: A theory of freedom and control, New York, Academic Press. P. 27-287.
27. Miron, AM and Brehm, JW. (2006). Reactance theory-40 years later, Zeitschrift für Sozialpsychologie, 37(1): 9-18.
28. Kivetz, R. (2005). Promotion reactance: The role of effort-reward congruity, Journal of consumer research, 31(4): 725-736.
29. Haisley E. and Lowenstein G. (2011). It's Not What You Get but When You Get It: The Effect of Gift Sequence on Deposit Balances and Customer Sentiment in a Commercial Bank, Journal of Marketing Research , 48(1): 103-115.
30. Moskop JC, Iserson KV, Aswegan AL, Larkin GL and Schears RM (2012), Gifts to physicians from industry: the debate evolves, Annals of Emergency Medicine , 59(2): 89-97.
31. Larsen D. and Watson JJ (2001), A guide to mapping the terrain of gift value, Psychology and Marketing , 18(8): 889-906.
32. UN World Urbanization Prospects, (2022). 2022 Revision of the World Population Prospects
33. Symec (2024). Activity Report No. 2, National Union of Physicians of Cameroon. Yaoundé, 2024.
34. Morgan MA, Dana, J., Loewenstein, G., Zinberg, S. and Schulkin J., (2006). Interactions of doctors with the pharmaceutical industry. J Med Ethics 2006;32: 559–563. doi: 10.1136/jme.2005.014480.
35. Mikhael EM, Alhilali DN. (2014). Gift acceptance and its effect on prescribing behavior among Iraqi specialist physicians. Pharmacol Pharm. 2014; 5(7 ): 705 – 15.
36. Atia, A., Malath, G. and Esra A. (2021). Influence of medical representatives on prescribing Practices in Tripoli. JAPR / Sec. D. 2022, 6 (1), 28-33
37. Khazzak, M. (2019). Pharmaceutical marketing strategies' influence on physicians' prescribing pattern in Lebanon: ethics, gifts, and samples BMC Health Services Research. doi.org/10.1186/s12913-019-3887-6
38. Makowska, M., Kaczmarek E. and Rodzinka, M. (2014). Transparency or restrictive gifts? Polish medical students' opinions about regulating relationships with pharmaceutical sales representatives. Monash Bioethics Review (2022) 40 (Suppl 1 ):S 49–S70 https://doi.org/10.1007/s40592-021-00128-2
39. Kaczmarek, E. (2019). Conflicts of interest, impartiality and trust. In shedding light on transparent cooperation in healthcare. The way forward for sunshine and transparency laws across Europe , ed. M. Rodzinka, M. Fallon-Kund & C. Marinetti. Brussels: Mental Health Europe, Europe, 52–55.
40. Qayyum, R., Thomas, PA., Dorman, T., Ratanawongsa, N., Wilson L., Bass, EB. and Marinopoulos, SS. (2007). Effectiveness of simulation in medical education. Journal of General Internal Medicine 2007; 22:83
41. Marlow, B. (2004), The future sponsorship of CME in Canada: Industry, government, physicians or a blend? Canadian Medical Association Journal 2004; 171: 150-1.
42. Steinbrook, R. (2008). Financial support of Continuing Medical Education. Jama-Journal of the American Medical Association 2008; 299: 1060-2
43. Etain B., Guittet, L., Weiss, N., Gajdos, V. and Katsahian, S. (2014). Attitudes of Medical Students towards Conflict of Interest: A National Survey in France. PLoS ONE 9(3 ): e92858. doi: 10.1371/journal.pone.0092858.
44. Ghaith, A. (2020). Investigating the Effect of Pharmaceutical Companies' Gifts on Doctors' Prescribing Behavior in Jordan. Humanitarian and Natural Sciences Journal 2 July, 2020, pp.001-009
45. ASSM. (2009). Correct sponsorship of continuing education: a “checklist ” to clarify the situation. Swiss Medical Bulletin. 2009; 90(34 ): 1282–3.
46. Reinhart, W. and Amstad, H. (2008). “I am registering for the continuing education course. I am a vegetarian.” Activity report of the consultation office and the advisory committee for the implementation of the guidelines “Medical profession–industry collaboration” Swiss Medical Bulletin. 2008; 89(35 ): 1490–92.
47. Legifrance, (1993). Law containing various social measures. Law No. 93-121. January 27, 1993.
48. Bonnard, A. (2010). The "DMOS" Law or the "Anti-Gift" Law. http://farmv.fr/docs/lyon2010/DMOS.pdf. [Online] November 2010. [Accessed: March 13, 2012.]
49. Rothan, DJ., McDonald, WJ. and Berkowitz, CD. (2009). Professional medical associations and their relationships with industry. A proposal for controlling conflict of interest. JAMA. 2009;301: 1367–72.